Product Information
INVOKAMET 50-1,000 MG TABLET is a brand product labeled by Janssen Pharmaceuticals Inc., priced at $9.5383 per EA under NDC 50458054160. Its NADAC has been published 620 times since Nov 19, 2014.
FDA first approved this application on Aug 8, 2014.
Strength
50; 1000 mg/1; mg/1
Manufacturer
Janssen Pharmaceuticals Inc.NDC
50458054160
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA204353FDA Approved
8/8/2014
On Market Since
8/8/2014
Pharmacological Classes
Price Statistics
The NADAC for INVOKAMET 50-1,000 MG TABLET has been published 620 times since Nov 19, 2014, and over the history we have for it it has risen 92.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.5383 per EA |
|---|---|
| All-time high | $9.5848 (Mar 12, 2025) |
| All-time low | $4.9190 (Dec 17, 2014) |
| 52-week high | $9.5668 |
| 52-week low | $9.5371 |
| Median price | $8.3088 |
| Average price | $8.1107 |
| Largest weekly change | +9.9% (Feb 11, 2015) |
| Weeks tracked | 620 |
| Tracking since | Nov 19, 2014 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Janssen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
canagliflozin and metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INVOKAMET 50-1,000 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for INVOKAMET 50-1,000 MG TABLET, manufactured by Janssen Pharmaceuticals Inc., is $9.5383 per EA (NDC 50458054160), effective Sep 30, 2026.
How has the price of INVOKAMET 50-1,000 MG TABLET changed over time?
Over the history we have for it, the NADAC for INVOKAMET 50-1,000 MG TABLET has risen 92.7%. It has been tracked across 620 weekly CMS publications since Nov 19, 2014.
What are the highest and lowest recorded NADAC prices for INVOKAMET 50-1,000 MG TABLET?
Since Nov 19, 2014, the NADAC for INVOKAMET 50-1,000 MG TABLET has ranged from a low of $4.9190 (Dec 17, 2014) to a high of $9.5848 (Mar 12, 2025), with a median of $8.3088 per EA.
Are there cheaper alternatives to INVOKAMET 50-1,000 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as INVOKAMET 50-1,000 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures INVOKAMET 50-1,000 MG TABLET?
INVOKAMET 50-1,000 MG TABLET (NDC 50458054160) is labeled by Janssen Pharmaceuticals Inc., and CMS classifies it as a brand product.